Genentech is laying off employees at its South San Francisco headquarters. According to a Worker Adjustment and Retraining Notification (WARN) Act notice, 118 staffers will lose their jobs effective Nov. 28.
All entries for: Oncology
October 28, 2025
Incyte Corp
Neutral Outlook
Wilmington, DE
1,001-5,000 employees
Further, in August 2022, the Inflation Reduction Act of 2022 was enacted, which includes provisions allowing the federal government to negotiate prices for certain high-expenditure single source Medicare drugs, to impose penalties and to implement a potential excise tax for manufacturers that fail to comply with the negotiation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law, and to impose rebate liability on manufacturers that take price increases that exceed inflation. The new law also reduced the out-of-pocket prescription drug costs for Medicare Part D beneficiaries, and to help pay for this change in benefit design, the law imposes a new discount program starting in 2025, in which manufacturers pay specified discounts on Medicare Part D utilization of their drugs as a condition of selling such drugs in the Medicare Part D program. The Inflation Reduction Act includes certain exemptions for small biotech drug manufacturers, including Incyte.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
October 28, 2025
Regeneron Pharmaceuticals
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
Notably, in 2022 the U.S. Congress passed the Inflation Reduction Act (“IRA”), which includes, among other items, provisions regarding the following:
•Implementation of a Medicare Drug Price Negotiation Program (the “Medicare Drug Price Negotiation Program”). The Medicare Drug Price Negotiation Program requires the government to set prices for select high-expenditure drugs covered under Medicare Parts B and D. Starting in 2023 and 2026, the government is authorized to select Part D and Part B drugs, respectively, for inclusion in the Medicare Drug Price Negotiation Program, with established prices to go into effect for selected Part D drugs in 2026 and for selected Part B drugs in 2028, in each case absent certain disqualifying events.
•Medicare Inflation Based Rebates. The IRA includes measures requiring manufacturers to pay rebates where increases to the average sales price or average manufacturer price of drugs covered under Medicare Parts B and D, respectively, exceed the rate of inflation.
•Medicare Part D Program Redesign. The IRA implements changes to the Medicare Part D benefits to limit patient out-of-pocket drug costs and shift program liabilities from patients to other stakeholders, including health plans, manufacturers, and the government.
Disease Area: Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
October 23, 2025
Alector
Layoffs
South San Francisco, CA
201-500 employees
GSK-partnered Alector will pull the plug on its investigational antibody latozinemab, which it had been developing for a genetic form of frontotemporal dementia, and cut 49% of its workforce. The layoffs will affect about 75 employees.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic
October 10, 2025
Ferring Pharmaceuticals
Layoffs
Saint-Prex, Switzerland
5,001-10,000 employees
Privately held Ferring Pharmaceuticals will part ways with up to 500 employees across its global operations in a bid to “sharpen” its strategic focus and gain “flexibility” as a company. The layoffs will mean an approximately 7% headcount reduction.
Disease Area: Endocrinology, Gastrointestinal, Hematology, Oncology
Drug Type: Biologic, Small Molecule
October 9, 2025
Nurix Therapeutics Inc
Neutral Outlook
San Francisco, CA
201-500 employees
It is unclear how future regulatory actions to implement the IRA, as well as the outcome of pending litigation against the IRA, may affect our products and future profitability, and we cannot predict the likelihood, nature, or extent of other health reform initiatives that may arise from future legislation or administrative actions.
Disease Area: Oncology
Drug Type: Small Molecule
October 3, 2025
Bolt Biotherapeutics
Layoffs
Redwood City, CA
51-200 employees
In an effort to extend its runway into 2027, California’s Bolt Biotherapeutics will let go of 50% of its employees. Around 20 workers will be affected, according to an SEC document, with the layoffs expected to be complete by the end of the year.
Disease Area: Oncology
Drug Type: Biologic
October 2, 2025
GSK
Layoffs
San Francisco, CA
50,001+ employees
Pharma giant GSK continues to shed employees, this time with an 8-person round of layoffs at its San Francisco, California site, according to a Worker Adjustment and Retraining Notification posting. The terminations were effective Sept. 29. GSK has enacted a couple of other workforce reductions this year.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
October 1, 2025
Sutro
Layoffs
South San Francisco, CA
201-500 employees
Sutro Biopharma is letting go of one third of its workforce. The South San Francisco–based company will use the money saved to focus on three antibody-drug conjugate programs, as well as its research and development collaborations. This is the second large-scale layoff for Sutro this year.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
September 29, 2025
Heidelberg Pharma
Layoffs
Ladenburg, Germany
51-200 employees
Ladenburg, Germany–based Heidelberg Pharma is laying off 75% of its staff after the company failed to meet the conditions for a royalty payment. Without the $70 million that royalty would have netted, Heidelberg is downsizing to extend its runway and focus its pipeline. The company has 122 employees, according to a May press release, so up to 92 employees will be affected. Heidelberg did not specify what conditions it missed, but in a financing agreement with HealthCare Royalty, Royalty would pay $70 million upon FDA approval of TLX250-CDx, Heidelberg’s radiolabeled version of the antibody girentuximab for clear cell renal cell carcinoma.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule